Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer BOULDER, Colo., Aug. 29, 2018 (GLOBE NEWSWIRE) -- A new study published in The Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell...

New Data Demonstrate the Biodesix VeriStrat® Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions - First Data Showing Prognostic Value of Test Among Patients by Performance Status Presented at ACMQ Annual Meeting –  - Optimizing Best Supportive Care and Avoiding Overtreatment Creates an Expected...

Interim Results from Biodesix® Study Indicate That VeriStrat Testing Impacts Treatment Decisions Across All Stages of Non-Small Cell Lung Cancer BOULDER, Colo., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Interim analysis of a new study examining the impact of VeriStrat testing on treatment decisions in patients with non-small cell lung cancer...

Lung Cancer: VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy BOULDER, Colo., July 10, 2017 (GLOBE NEWSWIRE) -- Clinical findings published in the peer reviewed journal Lung Cancer show that the Biodesix® VeriStrat test is prognostic for outcomes in patients...